Browsing by Author "Talip, Zeynep"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Deliverable 5.1 - Questionnaire on industrial and clinical key players and needs (v1.0).
    (2022-09-30) Radzina, Maija; Mamis, Edgars; Saule, Laura; Pajuste, Elīna; Kalniņa, Marika; Cocolios, Thomas; Talip, Zeynep; Stora, Thierry
    This document is a summary of responses received from the public known European industrial manufacturing and research institution and clinical facility representatives. The responses were given to the PRISMAP Consortium questionnaire disseminated in January-August 2022, approaching radionuclides and radiopharmaceutical manufacturers, research institutions and clinical end users in nuclear medicine, with the aim to identify potential stakeholders in the industrial and clinical communities interested by a coordinated approach in Europe such as PRISMAP. The summary from PRISMAP questionnaire stratifies the feedback from 114 respondents: radionuclide and radiopharmaceutical producers, research facilities and preclinical/clinical end users. In addition, it gives an insight into the location and capabilities of the main isotope-producing cyclotron facilities, many of which are known from the IAEA cyclotron database [2]). The questionnaire was offered with an opportunity to make new research and international collaboration partners, where all parties could benefit from harmonised supply and legislation procedures, expanding network and distribution routes, and subsequently gain visibility within the PRISMAP User Forum map at www.prismap.eu. The questionnaire was focused on the radionuclide use in medicine with emphasis on future needs for specific radionuclides and possible research developments with awareness of legislation, logistics and involved personnel education challenges and future perspectives.
  • No Thumbnail Available
    Item
    Novel radionuclides for use in Nuclear Medicine in Europe : where do we stand and where do we go?
    (2023-12) Radzina, Maija; Saule, Laura; Mamis, Edgars; Koester, Ulli; Cocolios, Thomas Elias; Pajuste, Elina; Kalnina, Marika; Palskis, Kristaps; Sawitzki, Zoe; Talip, Zeynep; Jensen, Mikael; Duchemin, Charlotte; Leufgen, Kirsten; Stora, Thierry; Rīga Stradiņš University
    BACKGROUND: In order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catalog of non-conventional radionuclides for medical and translational research. The aim of this article is to introduce readers with current status of novel radionuclides in Europe. MAIN BODY: A consortium questionnaire was disseminated through the PRISMAP consortium and user community, professional associations and preclinical/clinical end users in Europe and the current status of clinical end-users in nuclear medicine were identified. A total of 40 preclinical/clinical users institutions took part in the survey. Clinical end users currently use the following radionuclides in their studies: 177Lu, 68 Ga, 111In, 90Y, other alpha emitters, 225Ac, 64Cu and Terbium isotopes. Radionuclides that would be of interest for users within the next 2-5 years are 64Cu, Terbium radionuclide "family" and alpha emitters, such as 225Ac. CONCLUSIONS: Thanks to a questionnaire distributed by the PRISMAP consortium, the current status and needs of clinical end-users in nuclear medicine were identified.